Work

Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.3574

Authors: Anees Dauki, Mun Sang Yue, Reza Khosravan, Cixin He, Anwaar Saeed, Joel R. Hecht, Young Suk Park, Josep Tabernero, Cathy Eng, Michael Howland, Ahmed A. Othman

Institutions: Exelixis (United States), UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Exelixis

OpenAlex ID: W7162494153

Cites:

Cited by:

Related to: